Truist keeps a Buy rating with a $50 price target on Edgewise Therapeutics (EWTX) after the company’s updates on phase 2 data from the ongoing DMD – Duchenne muscular dystrophy – study, regulatory update on BMD – Becker Muscular Dystrophy – that was in-line with the firm’s base case, and data update from BMD OLE MESA. Truist notes that it expects the stock to be slightly weak on the regulatory feedback but also sees this as a buying opportunity, adding that given the data presented, the firm continues to see potential for sevasemten in both BMD and DMD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise drops 4% after FDA denies accelerated approval
- Edgewise Therapeutics announces results from sevasemten program
- Promising Developments in Edgewise Therapeutics’ Muscular Dystrophy Programs Drive Buy Rating
- Edgewise Therapeutics Reports Strong Q1 2025 Progress
- Edgewise Therapeutics reports Q1 EPS (43c), consensus (42c)